Discounted Cash Flow
Xeris Biopharma Holdings, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2020 | $20.2m | $-91.1m | $-80.9m | -452.2% | $-2.14 |
| 2021 | $49.3m (144.5%) | $-122.7m (-34.7%) | $-96.6m (-19.4%) | -249.0% (44.9%) | $-1.55 (27.6%) |
| 2022 | $110.2m (123.7%) | $-94.7m (22.9%) | $-103.4m (-7.0%) | -85.9% (65.5%) | $-0.70 (54.8%) |
| 2023 | $163.9m (48.7%) | $-62.3m (34.2%) | $-49.3m (52.3%) | -38.0% (55.8%) | $-0.45 (35.7%) |
| 2024 | $203.1m (23.9%) | $-54.8m (11.9%) | $-37.8m (23.2%) | -27.0% (28.9%) | $-0.37 (17.8%) |
| 2025 | $291.8m (43.7%) | $554.0k (101.0%) | $27.9m (173.8%) | 0.2% (100.7%) | $0.00 (100.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.